A Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Oxybutynin Vaginal Ring for Alleviation of Overactive Bladder Symptoms in Women

Faculty of 1000 evaluation for A Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Oxybutynin Vaginal Ring for Alleviation of Overactive Bladder Symptoms in Women.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718176906.793487117 ◽

2013 ◽

Author(s):

Altaf Mangera

Keyword(s):

Overactive Bladder ◽

Vaginal Ring ◽

Phase 2 ◽

Efficacy And Safety ◽

Safety Study ◽

Double Blind ◽

Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study

Neurourology and Urodynamics ◽

10.1002/nau.23852 ◽

2018 ◽

Vol 38 (1) ◽

pp. 295-304 ◽

Cited By ~ 7

Author(s):

Dong Gil Shin ◽

Hyeon Woo Kim ◽

Sang Jin Yoon ◽

Sang Hoon Song ◽

Young Ho Kim ◽

...

Keyword(s):

Overactive Bladder ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Bladder Symptoms ◽

Phase Iv

Faculty Opinions recommendation of OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006591.793478312 ◽

2013 ◽

Author(s):

Francisco Cruz

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double‐blind, randomized placebo‐controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study)

Neurourology and Urodynamics ◽

10.1002/nau.24552 ◽

2021 ◽

Author(s):

Sung Yong Cho ◽

Seong Jin Jeong ◽

Sangchul Lee ◽

Janghwan Kim ◽

Seong Ho Lee ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Clinical Efficacy and Safety of Imidafenacin as Add-on Treatment for Persistent Overactive Bladder Symptoms Despite α-Blocker Treatment in Patients With BPH: The ADDITION STUDY

Urology ◽

10.1016/j.urology.2013.05.008 ◽

2013 ◽

Vol 82 (4) ◽

pp. 887-893 ◽

Cited By ~ 27

Author(s):

Masayuki Takeda ◽

Osamu Nishizawa ◽

Momokazu Gotoh ◽

Masaki Yoshida ◽

Satoru Takahashi ◽

...

Keyword(s):

Overactive Bladder ◽

Clinical Efficacy ◽

Efficacy And Safety ◽

Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension

International Journal of Urology ◽

10.1111/iju.13499 ◽

2017 ◽

Vol 25 (3) ◽

pp. 251-257 ◽

Cited By ~ 1

Author(s):

Osamu Yokoyama ◽

Hidetomi Yamagami ◽

Shintaro Hiro ◽

Shinichi Hotta ◽

Masaki Yoshida

Keyword(s):

Overactive Bladder ◽

Elderly Women ◽

Efficacy And Safety ◽

Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration

BJU International ◽

10.1111/j.1464-410x.2010.09359.x ◽

2010 ◽

Vol 106 (9) ◽

pp. 1332-1338 ◽

Cited By ~ 23

Author(s):

Christopher R. Chapple ◽

Sender Herschorn ◽

Paul Abrams ◽

Joseph T. Wang ◽

Marina Brodsky ◽

...

Keyword(s):

Overactive Bladder ◽

Prostate Specific Antigen ◽

Extended Release ◽

Specific Antigen ◽

Efficacy And Safety ◽

Antigen Concentration ◽

LBA-03 EFFICACY AND SAFETY OF MIRABEGRON VS. PLACEBO ADD-ON THERAPY IN MEN WITH OVERACTIVE BLADDER SYMPTOMS RECEIVING TAMSULOSIN FOR UNDERLYING BENIGN PROSTATIC HYPERPLASIA (PLUS)

The Journal of Urology ◽

10.1097/01.ju.0000557495.41260.09 ◽

2019 ◽

Vol 201 (Supplement 4) ◽

Author(s):

Steven Kaplan* ◽

Sender Herschorn ◽

Kevin McVary ◽

David Staskin ◽

Christopher Chapple ◽

...

Keyword(s):

Benign Prostatic Hyperplasia ◽

Overactive Bladder ◽

Prostatic Hyperplasia ◽

Efficacy And Safety ◽

Faculty Opinions recommendation of Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717976336.793471350 ◽

2013 ◽

Author(s):

Alexander Roosen

Keyword(s):

Overactive Bladder ◽

Dose Escalation ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial ◽

Faculty Opinions recommendation of OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006591.793482693 ◽

2013 ◽

Author(s):

Hashim Hashim ◽

Riyad Almousa

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽